INTRODUCTION: CSS (CSS) is a rare neurodevelopmental disorder characterized by developmental delay, intellectual disability, hypotonia, distinctive craniofacial dysmorphism, and hypoplasia or aplasia of the distal phalanges or nails, particularly of the fifth digits. Pathogenic variants involving genes encoding components of the Switch/Sucrose Non-Fermentable chromatin-remodeling complex especially ARID1B gene critical for embryonic development and gene regulation represent the most common molecular cause of the syndrome. Although advances in genomic technologies have improved recognition of CSS worldwide over the past 3 decades, reports from sub-Saharan Africa remain limited.
CASE PRESENTATION: We report a male patient referred to Rwanda Military Teaching Hospital, Pediatric Department in Medical genetic unit for global developmental delay and feeding difficulties. Clinical examination revealed, hypotonia, developmental milestone delay, coarse facial appearance, sparse scalp hair, thick eyebrows, long eyelashes, broad nasal bridge, anteverted nostrils, low-set ears, micrognathia, and hypoplastic toenails.
Results: Conventional cytogenetic analysis demonstrated a male karyotype (46, XY). Whole exome sequencing-based copy number variants analysis identified a 7.3 Mb interstitial deletion involving chromosome 6q25.3–q25.1 encompassing the ARID1B gene. The finding was confirmed by multiplex ligation-dependent probe amplification, establishing the diagnosis of CSS type 1. The patient was managed in multidisciplinary team approach including physiotherapy and speech therapy and he demonstrated clinical improvement.
CONCLUSION: This report describes the first genetically confirmed case of CSS in Rwanda. It highlights the diagnostic utility of advanced molecular genetic testing in children with developmental delay and dysmorphic features and underscores the importance of expanding access to clinical genetic services in resource-limited settings to reduce diagnostic odyssey and timely patient management.
Adelaide Urugwiro Horanimpundu, Norbert Dukuze, Hannah Umutoni Mugaragu et al.· Rwanda medical journal· 0 citations
INTRODUCTION: Antimicrobial resistance is a growing global threat, with carbapenem-resistant
A. baumannii (CRAB) identified by World Health Organisation (WHO) as a top-priority pathogen. In
Rwanda, data on resistance patterns and underlying genetic determinants in A. baumannii remains
limited. This study aims to assess phenotypic resistance profile and detect key resistance genes to
support infection prevention and control (IPC) and antimicrobial stewardship interventions.
METHODS: A cross-sectional study was conducted from February to July 2025.Acinetobacter
baumannii isolates were identified and tested for antimicrobial susceptibility using the disk
diffusion method. Polymerase chain reaction (PCR) was used to detect selected resistance genes.
Data on patient demographics, sample types, and hospital wards were collected and analysed.
RESULTS: Of 1746 clinical isolates, 3.2% (n=56) were confirmed Acinetobacter baumannnii. Most
isolates were recovered from male Intensive Care Unit (ICU) patients aged 19–40. All isolates
showed 100% resistance to key beta-lactams, high resistance to ciprofloxacin with 87.0%,
gentamicin 78.3%, while complete susceptibility to imipenem at 100% was observed. Resistance
genes; blaOXA-23 and blaCTX-M were detected in 60.9% and 52.2% of isolates respectively,
confirming the genetic basis for carbapenem and ESBL resistance.
CONCLUSION: The study revealed a significant burden of multidrug-resistant Acinetobacter
baumannii infections, particularly among ICU patients. The high resistance of blaOXA-23 and blaCTX-M highlights the complexity of managing these infections and
underscores the need for strengthened IPC measures, routine molecular surveillance, and
targeted AMS strategies.
J. Uwimana, L. Mutesa, A. Ishimwe et al.· Rwanda medical journal· 0 citations